Scientists have uncovered a critical piece of the puzzle in autoimmune diseases: a protein that helps release immune response ...

Culton and Myers stressed the importance of raising awareness about these rare diseases and of getting more physicians and ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle ...

The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Rage and autoimmune disease: is there a link between suppressed anger and the women’s health crisis? - In the midst of a ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

The oral mucosa represents a fascinating scenario in the setting of medical research for its peculiar immune mileu. Not only the oral cavity hosts specific immune cells interacting with the local ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...